medigraphic.com
ISSN 1810-2352 (Print)

2013, Number 4

<< Back Next >>

Rev Cub Med Int Emerg 2013; 12 (4)

Candidemia behaviour in an intensive care unit

Ramirez SY, Larrondo MH, Halley PMC, Hidalgo CT, León PDO

Language: Spanish
References: 25
Page:
PDF size: 264.85 Kb.


ABSTRACT

Introduction: Invasive candidiasis has increased and although C. albicans is the most common, species as C. non albicans antifungal resistant are emerging. Objective: To characterize clinical and microbiologically the patients with candidemia. Method: A longitudinal, descriptive and prospective study of 52 patients admitted between January/2006-December/2009 was conducted. Results: 29 (55.8%) women and 23 men (44.2%). The mean age was 56.8±17.013 years and 26 had length of stay greater than 15 days, 34/65.4% had scores greater than 12 from Sevilla Scale. 35 patients died (67.3%), most (36/69, 2%) had C. non-albicans, 41 required mechanical ventilator assistance, 9 (22%) survived and 32 (78%) died (p = 0.003). There was an increased mortality in patients with C. non albicans (p = 0.016). Although antifungal resistance was not elevated, it was higher in the C. non albicans species. Multiorgan dysfunction was present in 43 (72.1%) who received specific treatment while 12 (27.9%) received empirical treatment. Among patients without multiorgan dysfunction, 7 (77.8%) were treated empirically and 2 (22.2%), with specific treatment (p=0.008). Conclusions: The majority of the patients in the group with empirical treatment survived meanwhile the majority of the patients in the group who received the specific treatment.


REFERENCES

  1. Aguado JM, Ruiz-Camps I, Muñoz P, Mensa J, Almirante B, Vázquez L, et al. Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011. Enferm Infecc Microbiol Clin. 2011;29(5):345–361.

  2. Garnacho J, León C. Resumen de las recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico: una visión multidisciplinar. Farm Hosp. 2005;29:283-9.

  3. Ylipalosaari P, Alakokko TI, Karhu J, Koskela M, Laurila J, Ohtonen P, et al. Comparison of the epidemiology, risk factors, outcome and degree of organ failures of patients with candidemia acquired before or during ICU treatment. Critical Care. 2012;16:R62.

  4. Pfaller MA, Diekema DJ. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin Microbiol Rev. 2007;20:133-63.

  5. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, et al. The Barcelona Candidemia Project Study Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2006;43:1829-1835.

  6. Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, et al. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Medical Mycology. 2012 Jan;50(1):50-55.

  7. Leroy O, Gangneux JP, Montravers P, Mira JP, Sollet JP, AmarCand Study Group. Epidemiology, management and risk factors for death of invasive Candida infectionsin critical care: a multicenter, prospective, observational study in France 2005-2006. Crit Care Med. 2009;37(5):1612-8.

  8. Marriott JE, Geoffrey Playford E, Chen S, Slavin M., Ellis D, for the Australian Candidaemia Study. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Critical Care. 2009;13:115-123.

  9. Hernández B, Prieto M , Muñoz J, Curriel E, Mora J. Clinical, Epidemiological and Taxonomic aspects of systemic Candidiasis in an Intensive Care Unit. Medicrit. 2008;5(1):1-12.

  10. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl JP, Francais A, et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Critical Care Medicine. 2012 Mar;40(3):813–822.

  11. Ostrosky-Zeichner L. Systemic antifungal therapy in patients without documented invasive fungal infection: A peek into the world of empirical antifungal therapy. Critical Care Medicine. 2012 Mar;40(3):997–8.

  12. Palomar M, Alvárez F, Olaechea P, Insausti J. Estudio Nacional de Vigilancia de Infección Nosocomial en Servicios de Medicina intensiva. Grupo de trabajo de Enfermedades Infecciosas de la Sociedad Española de Medicina Intensiva Crítica y Unidades Coronarias (SEMICYUC).[monografía en Internet]: Envin-Helics; 2007 [citado 21 Sept 2010]: Disponible en: http://www.semicyuc.org

  13. León C, Ruiz-Santana S, Saavedra S, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006; 34:730-7.

  14. Stratman C, Martin A, Rapp P, Berger R, Magnuson. Candidemia incidence in recipients of parenteral nutrition. Nutr Clin Pract. 2010;25(3):282-9.

  15. Sobel JD: The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Curr Infect Dis Rep. 2006;8:427-433.

  16. Pernán J. Aspectos epidemiológicos de las micosis en el paciente crítico. Rev Esp Quimioter. 2008;21(1):7-8.

  17. Trofa D, Gacser A, Nosanbuck D. Candida parapsilosis and emerging fungal pathogen. Clin Microbiol Rev. 2008;21(4):606.

  18. Garnacho J,Diaz A, Garcia E,Ruiz M, Hernandez C, Aznar J et al. Risk factors for Fluconazole resistant candidemia. Antimicrob Agents Chemoter. 2010;54(8):3149- 54.

  19. Kothavade J, Kura M, Valand G, Panthaki H. Candida tropicalis: Its prevalence, pathogenicity and increasing resistance to fluconazole. J Med Microbiol. 2010;59(8):873-880.

  20. Hajjeh RA, Sofair AN, Harrison LH, Marshall G, Arthington-Skaggs BA, Mirza SA, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population based active surveillance program. J Clin Microbiol. 2004;42:1519-27.

  21. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. The SENTRY Participant Group International surveillance of blood stream infections due to Candida species: frequency of occurrence and in vitro susceptibility to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through

  22. 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001;39: 3254-3259.

  23. Zaragoza R, Pemán J. Micosis invasoras en el paciente crítico. Rev Iberoam Micol. 2012;29(2):69-70.

  24. Silke Schelenz. Management of candidiasis in the intensive care unit. Journal of Antimicrobial Chemotherapy. 2008;61(1):31–33.

  25. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF. Clinical Practice guidelines for the management of candidiasis 2009 update by the infectious diseases Society of America. C Infect Dis. 2009;48(5):503-535.




2020     |     www.medigraphic.com